Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 026

Next Previous
Drug Profile

MT 026

Alternative Names: Anti-IL13 receptor alpha-2 chimeric antigen receptor T cell therapy - Suzhou Maximum Bio-tech; Anti-interleukin13 receptor alpha-2 CAR-T cell therapy - Maximum Bio-tech; CAR T cell therapy targeting IL13 receptor alpha-2 - Maximum Bio-tech; IL-13 receptor α2 therapy - Suzhou Maximum Bio-tech; IL-13R alpha 2 CAR-T therapy; IL13Rα2- specific CAR-T cells - Maximum Bio-tech; MT-026 - Suzhou Maximum Bio-tech; MT026

Latest Information Update: 26 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Maximum Bio-tech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioma
  • No development reported Brain metastases

Most Recent Events

  • 26 Feb 2026 MT 026 is still in phase I trials for Glioma in China (T-maximum Pharmaceuticals pipeline, February 2026)
  • 26 Feb 2026 No development reported - Preclinical for Brain metastases in China (Parenteral)
  • 06 Jan 2026 Efficacy, pharmacodynamics and adverse event data from a phase I trial released by Suzhou Maximum Bio-tech

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top